Navigation Links
ULURU Inc. Obtains Status of Approved Supplier With McKesson.
Date:12/3/2009

ADDISON, Texas, Dec. 3 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE ULU) announced today that McKesson Medical-Surgical, Inc., one of the major pharmaceutical distributors in the United States, has approved ULURU Inc. to be one of its suppliers and has placed its first significant order for Altrazeal(TM). McKesson Medical-Surgical delivers a comprehensive offering of medical-surgical supplies, medical equipment and health care technology-related services to the alternate site market, including physician offices, surgery centers, long-term care facilities and home care businesses throughout the United States.

Renaat Van den Hooff, President and CEO of ULURU Inc., commented: "This is an important milestone for the commercialization of Altrazeal(TM) since it will open up new business channels in the Home Health Care, Long Term Care and Physician Office Markets."

Altrazeal(TM) is an innovative breakthrough wound dressing, designed for greater effectiveness in wound closure by promoting an optimal moist wound healing environment, reducing pain and enhancing patient comfort, ease of application and removal and, in most cases, not requiring a secondary dressing.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex(TM) Aggregate technology and OraDisc(TM) transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal(TM), please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the commercialization of Altrazeal(TM). These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in ULURU Inc.'s Annual Report on Form 10-K for the year ended December 31, 2008, and other reports filed by us with the Securities and Exchange Commission.



Contact: Company
----------------
Renaat Van den Hooff
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145


SOURCE ULURU Inc.


'/>"/>
SOURCE ULURU Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
4. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
5. Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial
6. First Molecular Tem-PCR Test to Identify Multiple Forms of Staph and MRSA Obtains CLIA Certificate
7. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
8. STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany
9. DSM Obtains Exclusive World-Wide License for Innovative Drug Delivery Technology
10. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
11. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , April 29, 2016 ... Directeur Financier Sanofi, leader ... publie ses résultats pour le premier ... Groupe, Jérôme Contamine, commente les résultats ... les perspectives pour le reste de ...
(Date:4/28/2016)...  While Abbott,s announced purchase of St. Jude ... and stent business, healthcare research firm Kalorama Information ... into patient monitoring.  Kalorama said that patient monitoring ... with double-digit growth expected the next 5 years, ... Patient Monitoring . Abbott Laboratories agreed to ...
(Date:4/28/2016)... NEW YORK , April 28, 2016  The ... reached 275 million dollars, according to Kalorama Information and ... includes typing, immunoassays and nucleic acid testing.  The healthcare ... had made progress in developing blood collection stations and ... was made in Kalorama Information,s report, Blood ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... 30, 2016 , ... Create an abstract shape animation with ... manipulate three-dimensional shapes with ease all within Apple Motion . Users have ... texture animation, opacity texture animation, overall shape texture displacement, twist, camera controls, and ...
(Date:4/30/2016)... Cambridge, MA (PRWEB) , ... April 30, 2016 ... ... non-profit organization, today announced RANKED Health , a program to critically evaluate ... A major goal of the program is to provide independent, unbiased and accurate ...
(Date:4/30/2016)... Montego Bay, Jamaica (PRWEB) , ... April 30, ... ... Caribbean University, and Duane Boise, President and CEO of EMED, today signed a ... in Jamaica. , EMED and the Northern Caribbean University Department of Natural and ...
(Date:4/30/2016)... ... ... is a challenge for all of us, but there are things we can do to improve ... “Research is showing more and more that there are simple, yet important steps that can be ... Top priorities Dr. Kohli’s recommends for her patients include;, , exercise ...
(Date:4/29/2016)... ... April 30, 2016 , ... World Patent Marketing ... Up Springboard, an automotive invention that improves the storage features of a pick ... billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing. "Over ...
Breaking Medicine News(10 mins):